SCHEMBL21596859

SCHEMBL21596859

Cc1cc2c(N)noc2cc1-c1ccccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 1/20 0.44
NPC1 O15118 7/20 0.43
PKM P14618 6/20 0.43
RAB9A P51151 5/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MITF O75030 1/20 0.43
GAA P10253 1/20 0.43
KDM4E B2RXH2 4/20 0.40
TP53 P04637 6/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
TSHR P16473 1/20 0.38
KCNA3 P22001 1/20 0.38
GRM5 P41594 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
EDNRA P25101 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29652518 1.00 TDO2 (0.44) TDO2NPC1PKMRAB9ASMN1; SMN2
SCHEMBL21596937 0.79 TDO2 (0.47) TDO2NPC1PKMRAB9ASMN1; SMN2
SCHEMBL21596874 0.77 PIK3CD (0.43) TDO2NPC1PKMRAB9ASMN1; SMN2
SCHEMBL29652589 0.77 PIK3CD (0.43) TDO2NPC1PKMRAB9ASMN1; SMN2
SCHEMBL17427076 0.76 KDM4E (0.57) TDO2NPC1PKMRAB9ASMN1; SMN2
SCHEMBL30776779 0.74 KDM4E (0.55) TDO2NPC1PKMRAB9ASMN1; SMN2
SCHEMBL13581443 0.74 KDM4E (0.55) TDO2NPC1PKMRAB9ASMN1; SMN2
SCHEMBL25395443 0.73 KDM4E (0.47) TDO2NPC1PKMRAB9ASMN1; SMN2
SCHEMBL21596805 0.72 CFTR (0.36) GSK3BCHEK1MAP4K4ABL1NTRK1
SCHEMBL29652442 0.72 CFTR (0.36) GSK3BCHEK1MAP4K4ABL1NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 US disclosed
US-12365655-B2 Compounds CTXT PTY LTD (AU) 2025-07-22 US disclosed
EP-4335439-A2 COMPOUNDS CTXT PTY LTD (AU) 2024-03-13 EP disclosed
EP-3810602-B1 COMPOUNDS CTXT PTY LTD (AU) 2023-11-01 EP disclosed
EP-3810602-B1 COMPOUNDS CTXT PTY LTD (AU) 2023-11-01 EP disclosed
US-20220153710-A1 Compounds CTXT PTY LTD (AU) 2022-05-19 US disclosed
US-20220153710-A1 Compounds CTXT PTY LTD (AU) 2022-05-19 US disclosed
EP-3810602-A1 COMPOUNDS CTXT Pty Limited (AU) 2021-04-28 EP disclosed
CN-112334466-A Compound (I) CTXT私人有限公司 2021-02-05 CN disclosed
US-20200039945-A1 Compounds CTXT PTY LIMITED (AU) 2020-02-06 US disclosed
US-20200039945-A1 Compounds CTXT PTY LIMITED (AU) 2020-02-06 US disclosed
WO-2019243491-A1 COMPOUNDS CTXT PTY LIMITED (AU) 2019-12-26 WO disclosed
WO-2019243491-A1 COMPOUNDS CTXT PTY LIMITED (AU) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153710-A1 Compounds SLC10A1, ABCB11, PCSK9 TDO2 3526/4885NPC1 28/4885PKM 1105/4885
US-20200039945-A1 Compounds SLC10A1, ABCB11, PCSK9 TDO2 3523/4885NPC1 28/4885PKM 1103/4885
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B TDO2 3680/4885NPC1 10/4885PKM 3865/4885
US-12365655-B2 Compounds SLC10A1, ABCB11, PCSK9 TDO2 3523/4885NPC1 28/4885PKM 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.